Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001724310Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE INFORMATIONSubmission Contact InformationIs the second second

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer	Denali Therapeutics Inc.
SEC File Number	001-38311
Address of Issuer	161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	(650) 866-8548
Name of Person for Whose Account the Securities are To Be Sold	Watts Ryan J.

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Relationship to Issuer Officer Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Securities
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	25000	625000.00	136677646	04/20/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the	Date you	Nature of	Name of	Is	Date	Amount of	Date of	Nature of
Class	Acquired	Acquisition	Person from	this	Donor	Securities	Payment	Payment *

	Transaction	Whom Acquired	a Acquire Gift?	d Acquired	
Common	04/20/2023 Employee Stock Option Exercise	Denali Therapeutics Inc.		25000	Broker Payment 04/20/2023 for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

	Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
1	RYAN J WATTS 61 Oyster Point Blvd South San Francisco CA 94080	Denali Therapeutics Inc.	02/09/2023	3433	105018.00
1	RYAN J WATTS 61 Oyster Point Blvd Jouth San Francisco CA 94080	Denali Therapeutics Inc.	02/10/2023	25000	727575.00
1	RYAN J WATTS 61 Oyster Point Blvd, South San Francisco CA 94080	Denali Therapeutics Inc.	02/13/2023	33815	1017289.00

144: Remarks and Signature

Remarks	The options covered by this filing, may be sold over various dates.
Date of Notice	04/20/2023
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/18/2022
ATTENTION:	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

RYAN J WATTS

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)